Federal Register / Vol. 76, No. 53 / Friday, March 18, 2011 / Notices 14977 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 877– 

222–7570. Information requests can also 

be submitted by e-mail to 

DCAS@CDC.GOV. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2011–6369 Filed 3–17–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 76, FR 1167, dated 

January 7, 2011) is amended to reflect 

the reorganization of the National 

Center for Emerging and Zoonotic 

Infectious Diseases, Office of Infectious 

Diseases, Centers for Disease Control 

and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

Delete in their entirety the titles and 

functional statements for the Division of 

Healthcare Quality Promotion (CVLD) 

and insert the following: 

Division of Healthcare Quality 

Promotion (CVLD). The mission of the 

Division of Healthcare Quality 

Promotion (DHQP) is to protect patients; 

protect healthcare personnel; and 

promote safety, quality, and value in 

both national and international 

healthcare delivery systems. In carrying 

out its mission, DHQP: (1) Measures, 

validates, interprets, and responds to 

data relevant to healthcare-associated 

infections (HAI); antimicrobial 

resistance; adverse drug events; blood, 

organ and tissue safety; and 

immunization safety; and other related 

adverse events or medical errors in 

healthcare affecting patients and 

healthcare personnel; (2) investigates 

and responds to emerging infections and 

related adverse events among patients 

and healthcare personnel; (3) develops 

and maintains the National Healthcare 

Safety Network (NHSN), a tool for 

monitoring healthcare-associated 

infections, measuring healthcare 

outcomes and processes, and 

monitoring healthcare worker 

vaccination and selected health 

measures in healthcare facilities; (4) 

assesses rates of infections caused by 

resistant-bacteria in the U.S. through 

active surveillance, review of national 

healthcare data sets, and laboratory 

surveillance programs; (5) conducts 

epidemiologic, and basic and applied 

laboratory research to identify new 

strategies to prevent infections/ 

antimicrobial resistance, and related 

adverse events or medical errors, 

especially those associated with medical 

or surgical procedures, indwelling 

medical devices, contaminated 

products, dialysis, and water; (6) 

collaborates with academic and public 

health partners to design, develop, and 

evaluate the efficacy of interventions for 

preventing infections and reducing 

antimicrobial resistance, and related 

adverse events or medical errors; (7) 

develops and disseminates evidencebased guidelines and recommendations 

to prevent and control HAT, 

antimicrobial resistance, and related 

adverse events or medical errors; (8) 

promotes the nationwide 

implementation of Healthcare Infection 

Control Practices Advisory Committee 

(HICPAC) recommendations and other 

evidence-based interventions to prevent 

HAI, antimicrobial resistance, and 

related adverse events or medical errors 

among patients and healthcare 

personnel; (9) evaluates the impact of 

evidence-based recommendations and 

interventions across the spectrum of 

healthcare delivery sites; (10) develops, 

implements, and evaluates the 

effectiveness of interventions to prevent 

transmission of healthcare-associated 

human immunodeficiency virus (HIV) 

and other bloodborne pathogen, 

infections; (11) serves as the National 

Reference Laboratory for the 

identification and antimicrobial 

susceptibility testing of staphylococci, 

anaerobic bacteria, non-tuberculous 

mycobacterial, and those gram-negative 

bacilli causing healthcare associated 

infections; (12) serves as the technical 

reference laboratory for detection and 

characterization of other pathogens 

related to healthcare; and for 

characterizing the contribution of the 

healthcare environment to HAI; (13) 

coordinates guidance and research 

related to infection control across the 

agency and with national and 

international partners; (14) monitors 

vaccine safety and conducts research to 

evaluate the safety of available and new 

vaccines; (15) promotes the integration 

of the healthcare delivery system in 

federal/state/local public health 

preparedness planning; (16) trains 

Epidemic Intelligence Service Officers 

and other trainees; (17) coordinates 

antimicrobial resistance activities at 

CDC; (18) works in a national leadership 

capacity with public and private 

organizations to enhance antimicrobial 

resistance prevention and control, 

surveillance and response, and applied 

research; (19) coordinates blood, organ, 

and other tissue safety at CDC; and (20) 

provides expertise arid assistance to 

HHS and other Federal agencies on 

efforts and activities related to health 

reform. 

Office of the Director (CVLD1). (1) 

Manages, directs, and coordinates the 

activities of the DHQP; (2) provides 

leadership and guidance on policy and 

communications/media; (3) works with 

Federal agencies, CDC’s Office of 

Prevention through Healthcare, and 

other partners on activities related to 

Health Reform; (4) coordinates state and 

local activities to monitor and prevent 

HAI; (5) provides liaison with other 

governmental agencies, international 

organizations, and other outside groups; 

(6) coordinates, in collaboration with 

the appropriate CIO and CDC 

components, global health activities 

relating to the prevention of healthcareassociated infections/antimicrobial 

resistance, and related adverse events or 

medical errors; (7) coordinates 

activities, guidance, emergency 

response, and research related to 

infection control in healthcare settings 

across the agency and with national and 

international partners; (8) works with 

other federal agencies, state 

governments, medical societies, and 

other public and private organizations 

to promote collaboration and to 

integrate healthcare preparedness in 

federal/state/local public health 

preparedness planning; (9) oversees the 

coordination of antimicrobial resistance 

activities at CDC; (10) represents CDC as 

co-chair of the federal Interagency Task 

Force on Antimicrobial Resistance; (11) 

coordinates with other agencies, state 

governments, medical societies, and 

other public and private organizations 

to enhance antimicrobial resistance 

prevention and control, surveillance 

and response, and applied research; (12) 

leads CDC’s activities on blood, organ, 

and other tissue safety; (13) represents 

CDC on the Advisory Committee on 

Blood Safety and Availability and the 

Advisory Committee on Organ 

Transplantation; (14) works with other 

federal agencies, state governments, and 


Emcdonald on DSK2BSOYB1PROD with NOTICES
14978 Federal Register / Vol. 76, No. 53 / Friday, March 18, 2011 / Notices 

other public and private organizations 

to enhance blood, organ, and other 

tissue safety through coordination of 

investigation, prevention, response, 

surveillance, applied research, health 

communication, and public policy; and 

(15) advises the Director, NCEZID, on 

science, policy and communication 

matters concerning DHQP activities. 

Program Implementation and 

Integration Activity (CVLD13). (1) 

Provides leadership and guidance for 

program planning and development, 

program management, and operations; 

(2) provides DHQP-wide administrative 

and program services and coordinates or 

ensures coordination with the 

appropriate CIOs and CDC staff offices 

on administrative and program matters 

including budget formulation and 

execution and human resource 

management; (3) oversees the 

coordination of federal and state 

programs and new initiatives to prevent 

HAI (e.g., the HAI Recovery Act State 

Cooperative Agreement program); (4) 

interprets general program and 

administrative policy directives for 

implications on management and 

execution of DHQP’s programs; (5) 

serves as lead and primary contact and 

liaison with relevant CDC staff offices 

on all matters pertaining to DHQP’s 

procurement needs and activities; (6) 

provides management and coordination 

for DHQP-occupied space and facilities 

including laboratory space and 

facilities; (7) provides oversight and 

management of the distribution, 

accountability, and maintenance of CDC 

property and equipment including 

laboratory property and equipment; and 

(8) provides program and administrative 

support for HICPAC. 

Clinical and Environmental 

Microbiology Branch (CVLDB). (1) 

Collaborates with the Prevention and 

Response Branch to provide laboratory 

response to outbreaks and emerging 

threats associated with infections/ 

antimicrobial resistance and related 

adverse events throughout the 

healthcare delivery system; (2) provides 

comprehensive laboratory support and 

expertise for investigations of 

recognized and emerging bacterial 

agents in healthcare settings; (3) 

develops methods to assess 

contamination of environmental surface; 

(4) investigates novel and emerging 

mechanisms of antimicrobial resistance 

among targeted pathogens found in 

healthcare settings; (5) detects toxins/ 

virulence factors of bacteria causing HAI 

to understand their transmission and 

pathogenicity; (6) conducts research in 

collaboration with partners to develop 

new, accurate methods of detecting 

antimicrobial resistance in bacteria and 

to improve reporting of antimicrobial 

susceptibility testing results to 

physicians to improve antimicrobial 

use; (7) conducts laboratory research to 

identify new strategies to prevent 

infections/antimicrobial resistance, 

related adverse events, and medical 

errors, especially those associated with 

invasive medical devices, contaminated 

products, dialysis, and water; (8) 

maintains capacity to evaluate 

commercial microbial identification and 

antimicrobial susceptibility testing 

systems and products and facilitates 

their improvement to provide accurate 

patient test results; (9) investigates the 

role of biofilms, particularly those 

detected in indwelling medical devices 

and medical water systems, in medicine 

and public health, and identifies novel 

methods to eliminate colonization and 

biofilm formation on foreign bodies; (10) 

investigates the role of the water 

distribution systems in healthcare 

facilities in order to understand and 

prevent waterborne healthcare 

associated infections; and (11) provides 

expertise, research opportunities, 

training, and laboratory support for 

investigations of infections and related 

adverse events to other CDC CIOs and 

to our partners in areas related to 

quality clinical microbiology laboratory 

practices, investigation of emerging 

pathogens and environmental 

microbiology. 

Prevention and Response Branch 

(CVLDC). (1) Coordinates rapid response 

to assess and control strategically 

selected outbreaks and emerging threats 

(i.e., healthcare associated infections, 

related adverse events, including related 

infections in the community, and 

antimicrobial resistance) and 

communicates the results of response 

activities with federal and state 

agencies, healthcare providers, and the 

public to prevent similar adverse events 

in the future; (2) supports local, state, 

and national efforts to prevent HAI and 

related adverse events using evidencebased recommendations; (3) develops 

and/or evaluates the effectiveness of 

interventions to prevent HAI and related 

adverse events or medical errors across 

the spectrum of healthcare delivery sites 

including acute and long-term inpatient 

care, dialysis, and ambulatory settings; 

(4) provides epidemiology support for 

investigation and study of both 

recognized and emerging bacterial 

healthcare pathogens and related 

community pathogens, including 

antimicrobial resistant forms of these 

pathogens; (5) provides epidemiology 

support to Clinical and Environmental 

Microbiology Branch to identify new 

strategies to prevent infections 

associated with indwelling medical 

devices, contaminated products, 

dialysis, and water; (6) develops, 

promotes, and monitors implementation 

of evidence-based guidelines/ 

recommendations, and other proven 

interventions to prevent HAI and related 

adverse events, and occupational 

infections/exposures among healthcare 

personnel; (7) develops, promotes, and 

monitors implementation of 

interventions to prevent transmission of 

healthcare-associated HIV infections 

and conducts case investigations of 

occupational HIV infections; (8) 

conducts and supports research and 

evaluates impact of public health 

practices to prevent HAIs and related 

adverse events and monitors progress in 

reaching national prevention goals; and 

(9) provides expert consultation, 

guidance, and technical support to other 

branches in the division, across the 

agency, to government (e.g., Centers for 

Medicare Services and the VA 

Administration) and non-governmental 

payers of healthcare, and other domestic 

and international partners, and the U.S. 

public on the epidemiology and 

prevention of HAI and related adverse 

events, and exposures/injuries among 

healthcare personnel. 

Surveillance Branch (CVLDD). (1) 

Monitors and evaluates on the national 

level the extent, distribution, and 

impact of healthcare-associated 

infections, antimicrobial use and 

resistance, adverse drug events, 

healthcare worker safety events, and 

adherence to clinical processes and 

intervention programs designed to 

prevent or control adverse exposures or 

outcomes in healthcare; (2) provides 

leadership and consultative services for 

statistical methods and analysis to 

investigators in the branch, division, 

and other organizations responsible for 

surveillance, research studies, and 

prevention and control of HAI and other 

healthcare-associated adverse events; (3) 

improves methods and enables wider 

use of clinical performance 

measurements by healthcare facilities 

and public health entities for specific 

interventions and prevention strategies 

designed to safeguard patients and 

healthcare workers from risk exposures 

and adverse outcomes through 

collaborations with extramural partners; 

(4) collaborates with public and private 

sector partners to further standardize, 

integrate, and streamline systems by 

which healthcare organizations collect, 

manage, analyze, report, and respond to 

data on clinical guideline adherence, 

HAI, including transmission of multidrug resistant organisms and other HAI; 

(5) coordinates, further develops, 


Emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 53 / Friday, March 18, 2011 / Notices 14979 

enables wider use, and maintains NHSN 

to obtain scientifically valid clinical 

performance indices and benchmarks 

that promote healthcare quality and 

value at the facility, state, and national 

levels; (6) conducts applied research to 

identify and develop innovative 

methods to detect and monitor HAI and 

antimicrobial resistance; (7) conducts 

special studies and provides national 

estimates of targeted, healthcareassociated adverse events, antimicrobial 

use and resistance patterns, and the 

extent to which prevention and control 

safeguards are in use to protect at-risk 

patients across the spectrum of 

healthcare delivery sites; (8) uses NHSN 

and other data sources to conduct 

special studies and provide national 

estimates of targeted occupational 

illnesses and injuries among healthcare 

workers and the extent to which 

preventive safeguards are in use across 

the spectrum of healthcare delivery 

sites; and (9) leads CDC’s national 

adverse drug events surveillance 

activities and seeks to translate 

population-based surveillance data into 

evidence-based policies and targeted, 

innovative and collaborative 

interventions. 

Immunization Safety Office (CVLDE). 

(1) Assesses the safety of new and 

currently available vaccines received by 

children, adolescents and adults; (2) 

coordinates vaccine safety activities at 

CDC; (3) conducts public health 

surveillance to identify adverse events 

following immunization; (4) in 

collaboration with the Food and Drug 

Administration, coordinates and 

maintains the Vaccine Adverse Event 

Reporting System, a national reporting 

system that serves as an early-warning 

system to detect medical problems that 

may be related to vaccines; (5) 

coordinates and maintains the Vaccine 

Safety Datalink, a collaborative effort 

with managed care organizations, to 

assess adverse events following 

immunization; (6) administers the 

Clinical Immunization Safety 

Assessment network, a national network 

of medical research centers with 

expertise in immunization safety 

conducting clinical research on 

immunization-associated health risks; 

(7) participates in the Brighton 

Collaboration, an international 

collaboration of scientists from around 

the world working to develop, evaluate, 

and disseminate globally accepted 

standard case definitions for adverse 

events following immunization and 

guidelines for collection, analysis, and 

presentation of vaccine safety data; and 

(8) works with other federal agencies, 

state governments, and other public and 

private organizations to assess and 

promote the safety of vaccines. 

Dated: March 10, 2011. 

James D. Seligman, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–6179 Filed 3–17–11; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Muscular Dystrophy Coordinating 

Committee (MDCC). 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

inform the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: April 20, 2011. 

Time: 8 a.m. to 4:30 p.m. 

Agenda: The 2011 meeting of the MDCC 

will review Federal agency activities in the 

muscular dystrophies, brief participants on 

the NIH grant database, NIH RePORTER, 

discuss therapy development resources at the 

NIH, and review joint NIH/FDA activities 

and initiatives in rare diseases. The MDCC 

will also discuss new opportunities in 

therapy development based upon a 

representative example of a new mechanistic 

finding and the lessons learned in current 

drug development programs. A panel will 

review and discuss the challenges of 

conducting clinical trials in the muscular 

dystrophies. 

An agenda will be posted prior to the 

meeting on the MDCC Web site: http:// 

www.ninds.nih.gov/find_people/groups/ 

mdcc/index.htm. 

Place: Hilton Rockville Hotel & Executive 

Meeting Center, 1750 Rockville Pike, 

Rockville, Maryland 20852–1699. 

Contact Person: John D. Porter, PhD, 

Executive Secretary, Muscular Dystrophy 

Coordinating Committee, National Institute 

of Neurological Disorders and Stroke, NIH, 

6001 Executive Boulevard, NSC 2172, 

Bethesda, MD 20892, (301) 496–5739, 

porterjo@ninds.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

their statement to the Contact Person listed 

on this notice. The statement should include 

the name, address, telephone number and 

when applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: March 11, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–6453 Filed 3–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Open Meeting Notice 

Notice is hereby given that the 

National Institutes of Health (NIH), 

Department of Health and Human 

Services, will hold a scientific 

workshop. 

Title: ‘‘State of the Knowledge 

Workshop on Myalgic 

Encephalomyelitis/Chronic Fatigue 

Syndrome (ME/CFS) Research’’. 

Dates: April 7–8, 2011. 

Time: 8 a.m. to 5 p.m. 

Place: Building 31, Conference Rooms 

6C8/9/10, NIH campus, Bethesda, 

Maryland. 

Purpose of the Meeting: This 

workshop will bring together subject 

matter experts who will discuss 

multiple aspects of ME/CFS, including 

epidemiology, etiology, 

pathophysiology, diagnosis, and 

treatment. The workshop panelists will 

identify gaps in knowledge and 

opportunities for advancing biomedical 

research. 

This workshop is open to the public. 

Please note that attendance is limited. 

We encourage registration for those 

attending in person (see Web address 

below). For those unable to attend, the 

workshop will be available via NIH 

VideoCasting (http://videocast.nih.gov/) 

both during and after the event. 

Individuals with disabilities who 

need reasonable accommodation should 

indicate their needs on registration or 

contact Infinity Conference Group by 

telephone at 703–925–9455, ext. 0, or email at icg@infinityconferences.com. 

For more information including an 

agenda, registration, and visitor 

information, please visit the workshop 

Web site: https:// 

www.infinityconferences.com/ 

InfiniBase/Templates/157557/ 

Index.htm. 

Contact Person: Dennis Mangan, PhD; 

Chair, Trans-NIH ME/CFS Research 

Working Group, Office of Research on 


Emcdonald on DSK2BSOYB1PROD with NOTICES